Yip SM, et al. - In this retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) who were treated with ≥1 line of immuno-oncology (IO), researchers aimed to establish IO efficacy benchmarks and update patient outcomes in each International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic class. They used the IMDC database, which included data from 38 centers. They estimated overall response rates (ORRs), duration of treatment, and overall survival (OS). Based on IMDC prognostic factors, patients were stratified. No deterioration in ORR was seen from the first-line to the fourth-line of IO therapy. The IMDC criteria appropriately enabled patients stratification into favorable-risk, intermediate-risk, and poor-risk groups for OS in the second line through fourth line.